Answers are grounded in this paper and cite their sources.
Shows NS5806 activates TREK channels in neurons, suggesting broader potassium channel interactions.
NS5806 is a diaryl‐urea small molecule developed for the treatment of pain and neurological disorders. A potent activator of K v 4.3 potassium channels, it is widely used to study K v 4 channel physiology in excitable cells, including trigeminal neurons. Surprisingly, we found that NS5806 produced a significant, robust hyperpolarization of the resting membrane potential of all trigeminal neurons tested. Given the structural similarity of NS5806 to other negatively charged activator compounds with broad potassium channel activity, we investigated whether NS5806 might also modulate the two‐pore domain potassium (K2P) TREK channels, which are abundantly expressed in sensory neurons. Here we show that NS5806 activates both TREK‐1 and TREK‐2 channels. While NS5806 is described as a K v 4‐selective activator, our data suggest that its effects on trigeminal and other neurons may arise from concurrent activation of multiple potassium channel types, including TREK‐1 and TREK‐2.
No takes yet. Share an insight, caveat, or question.
Veale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: